Alzheimer disease is the most common form of dementia which can impair the person’s daily functioning and is mainly characterized by loss of memory, loss of cognitive function and functional impairment.
Global Alzheimer’s Disease Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Alzheimer’s Disease Antibodies Market Opportunity: > USD 5 Billion
- Alzheimer’s Disease Clinical Trials Insight: > 200 Drugs In Trials
- Alzheimer’s Disease Biomarkers Sourced During Clinical Trials
- Alzheimer’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1648033875
Alzheimer disease is the most common form of dementia which can impair the person’s daily functioning and is mainly characterized by loss of memory, loss of cognitive function and functional impairment. Currently, there is no cure for the disease; however there are several medications which have been approved by the regulatory bodies to relieve their symptoms. Alzheimer disease has become the fifth leading cause of death in world, and has become the world’s biggest nightmare with the increase in numbers every year. Presently, the management of Alzheimer disease consists mainly of symptomatic treatments of which there are six approved medications belonging to drug class acetylcholinesterases, NMDA, combination therapy, and Aβ A4 protein inhibitor.
Recently in 2021, US FDA has granted approval to Aduhelm as the first Alzheimer’s disease treatment to address the pathology of disease. Despite their targeted nature, the drug has not shown encouraging response in the market owing to its high cost and associated side effects. However, the introduction of this drug has spurred the competition among pharmaceutical giants to launch more targeted therapy in the market. Some of the promising Alzheimer’s Disease pipeline therapies include Lecanemab, Tricaprilin, Gantenerumab, Brexpiprazole, AL002, ALZT-OP, Brilaroxazine, BIIB076 , and others. These drugs belong to different classes such as Monoclonal Antibody, Peptides, Polymer, Small molecule, and Gene therapy.
The global Alzheimer disease market is highly competitive and consists of several key players including Allegran, Novartis, Biogen, AstraZencea, Bristol Myers Squibb, Takeda Pharmaceutical, amongst others. Since last few years, pharmaceutical and diagnostic giants have collaborated more than ever before to advance the commercial and clinical value of precision medicine. The rising strategic alliances among major pharmaceutical giants and increasing research and development activities offer great hope that promising new therapies can be accelerated through trials and approvals to the point of clinical care. For instance in 2022, Alchemab Therapeutics announced the extension of its collaboration with Medicines Discovery Catapult (MDC) to functionally characterize antibodies from resilient patients with Alzheimer disease and frontotemporal dementia, previously discovered using Alchemab pioneering platform
At present, cholinesterase inhibitors are dominating the market owing to large number of product approved associated with their high adoption rates. However, the entry of Aduhelm is expected to compete in the market owing to its high specificity and novel targeted mechanism of action. As per our analysis, several other disease modifying agents will enter the market during forecast period and will drive the growth of market. The robust clinical pipeline of more than 150 drugs with majority of them as disease modifying agent’s highlights the positive future treatment of the disease in coming years.
As per our report findings, the global Alzheimer disease market will surpass US$ 5 Billion by 2028. Population ageing across the globe is the major factor driving the market. In addition, rising life expectancy is also contributing to quick increase in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Apart from this, the rising investment by pharmaceutical giants for the development of novel targeted therapy and early diagnosis of the disease will also propel the growth of market. However, lack of skilled medical professionals and unfavorable reimbursement scenario will restrain the growth of market during the forecast period.
Our report provides a detailed review of the current market landscape of drugs developed for the treatment of Alzheimer’s, including analyses based on several relevant parameters, such as current status of development (marketed, clinical and pre-clinical), phase of development (phase IV, phase III, phase II/III, phase II, phase I/II and phase I) of lead candidates. The report also provides commercial information on the approved drug for Alzheimer along with their pricing and dosage.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366